vs

Side-by-side financial comparison of IAC Inc. (IAC) and Revvity (RVTY). Click either name above to swap in a different company.

Revvity is the larger business by last-quarter revenue ($772.1M vs $646.0M, roughly 1.2× IAC Inc.). Revvity runs the higher net margin — 12.7% vs -11.9%, a 24.6% gap on every dollar of revenue. On growth, Revvity posted the faster year-over-year revenue change (5.9% vs -10.5%). Revvity produced more free cash flow last quarter ($161.8M vs $31.4M). Over the past eight quarters, Revvity's revenue compounded faster (9.0% CAGR vs 1.7%).

IAC Inc. is an American holding company that owns brands worldwide, mostly in media and Internet. The company originated in 1996 as HSN Inc., the holding company of Home Shopping Network and USA Network before changing its name to USA Networks, Inc. in 1999. The firm's television assets then were sold to Vivendi in 2002.

Revvity, Inc. is an American company in the life sciences and diagnostics business that is focused on selling to the pharmaceutical and biotechnology industries, especially in relation to approaches making use of new cell therapy or gene therapy developments. Its origins lie with the long-existing company PerkinElmer, which has been in a variety of business lines.

IAC vs RVTY — Head-to-Head

Bigger by revenue
RVTY
RVTY
1.2× larger
RVTY
$772.1M
$646.0M
IAC
Growing faster (revenue YoY)
RVTY
RVTY
+16.3% gap
RVTY
5.9%
-10.5%
IAC
Higher net margin
RVTY
RVTY
24.6% more per $
RVTY
12.7%
-11.9%
IAC
More free cash flow
RVTY
RVTY
$130.4M more FCF
RVTY
$161.8M
$31.4M
IAC
Faster 2-yr revenue CAGR
RVTY
RVTY
Annualised
RVTY
9.0%
1.7%
IAC

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
IAC
IAC
RVTY
RVTY
Revenue
$646.0M
$772.1M
Net Profit
$-76.8M
$98.4M
Gross Margin
69.8%
Operating Margin
-17.5%
14.5%
Net Margin
-11.9%
12.7%
Revenue YoY
-10.5%
5.9%
Net Profit YoY
61.4%
3.9%
EPS (diluted)
$-0.96
$0.86

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IAC
IAC
RVTY
RVTY
Q4 25
$646.0M
$772.1M
Q3 25
$589.8M
$698.9M
Q2 25
$586.9M
$720.3M
Q1 25
$570.5M
$664.8M
Q4 24
$721.4M
$729.4M
Q3 24
$642.0M
$684.0M
Q2 24
$634.4M
$691.7M
Q1 24
$624.3M
$649.9M
Net Profit
IAC
IAC
RVTY
RVTY
Q4 25
$-76.8M
$98.4M
Q3 25
$-21.9M
$46.7M
Q2 25
$211.5M
$53.9M
Q1 25
$-216.8M
$42.2M
Q4 24
$-199.0M
$94.6M
Q3 24
$-243.7M
$94.4M
Q2 24
$-142.2M
$55.4M
Q1 24
$45.0M
$26.0M
Gross Margin
IAC
IAC
RVTY
RVTY
Q4 25
69.8%
Q3 25
64.8%
53.6%
Q2 25
65.6%
54.5%
Q1 25
64.0%
56.5%
Q4 24
65.8%
Q3 24
62.1%
56.3%
Q2 24
60.1%
55.7%
Q1 24
58.4%
54.6%
Operating Margin
IAC
IAC
RVTY
RVTY
Q4 25
-17.5%
14.5%
Q3 25
-3.5%
11.7%
Q2 25
0.1%
12.6%
Q1 25
6.3%
10.9%
Q4 24
6.7%
16.3%
Q3 24
1.3%
14.3%
Q2 24
-3.4%
12.4%
Q1 24
-10.2%
6.8%
Net Margin
IAC
IAC
RVTY
RVTY
Q4 25
-11.9%
12.7%
Q3 25
-3.7%
6.7%
Q2 25
36.0%
7.5%
Q1 25
-38.0%
6.4%
Q4 24
-27.6%
13.0%
Q3 24
-38.0%
13.8%
Q2 24
-22.4%
8.0%
Q1 24
7.2%
4.0%
EPS (diluted)
IAC
IAC
RVTY
RVTY
Q4 25
$-0.96
$0.86
Q3 25
$-0.27
$0.40
Q2 25
$2.57
$0.46
Q1 25
$-2.64
$0.35
Q4 24
$-2.36
$0.77
Q3 24
$-2.93
$0.77
Q2 24
$-1.71
$0.45
Q1 24
$0.51
$0.21

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IAC
IAC
RVTY
RVTY
Cash + ST InvestmentsLiquidity on hand
$960.2M
$919.9M
Total DebtLower is stronger
$1.4B
Stockholders' EquityBook value
$4.7B
$7.3B
Total Assets
$7.1B
$12.2B
Debt / EquityLower = less leverage
0.30×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IAC
IAC
RVTY
RVTY
Q4 25
$960.2M
$919.9M
Q3 25
$1.0B
$931.4M
Q2 25
$1.1B
$991.8M
Q1 25
$1.2B
$1.1B
Q4 24
$1.4B
$1.2B
Q3 24
$1.3B
$1.2B
Q2 24
$1.3B
$2.0B
Q1 24
$1.3B
$1.7B
Total Debt
IAC
IAC
RVTY
RVTY
Q4 25
$1.4B
Q3 25
$1.4B
Q2 25
$1.4B
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Stockholders' Equity
IAC
IAC
RVTY
RVTY
Q4 25
$4.7B
$7.3B
Q3 25
$4.8B
$7.4B
Q2 25
$4.9B
$7.6B
Q1 25
$4.7B
$7.6B
Q4 24
$5.6B
$7.7B
Q3 24
$5.8B
$7.9B
Q2 24
$6.0B
$7.9B
Q1 24
$6.1B
$7.8B
Total Assets
IAC
IAC
RVTY
RVTY
Q4 25
$7.1B
$12.2B
Q3 25
$7.2B
$12.1B
Q2 25
$7.4B
$12.4B
Q1 25
$7.2B
$12.4B
Q4 24
$9.7B
$12.4B
Q3 24
$9.8B
$12.8B
Q2 24
$10.2B
$13.4B
Q1 24
$10.4B
$13.4B
Debt / Equity
IAC
IAC
RVTY
RVTY
Q4 25
0.30×
Q3 25
0.30×
Q2 25
0.30×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IAC
IAC
RVTY
RVTY
Operating Cash FlowLast quarter
$36.6M
$182.0M
Free Cash FlowOCF − Capex
$31.4M
$161.8M
FCF MarginFCF / Revenue
4.9%
21.0%
Capex IntensityCapex / Revenue
0.8%
2.6%
Cash ConversionOCF / Net Profit
1.85×
TTM Free Cash FlowTrailing 4 quarters
$44.8M
$509.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IAC
IAC
RVTY
RVTY
Q4 25
$36.6M
$182.0M
Q3 25
$30.1M
$138.5M
Q2 25
$-2.8M
$134.3M
Q1 25
$63.0K
$128.2M
Q4 24
$110.1M
$174.2M
Q3 24
$95.3M
$147.9M
Q2 24
$85.0M
$158.6M
Q1 24
$64.1M
$147.6M
Free Cash Flow
IAC
IAC
RVTY
RVTY
Q4 25
$31.4M
$161.8M
Q3 25
$25.3M
$120.0M
Q2 25
$-7.2M
$115.5M
Q1 25
$-4.6M
$112.2M
Q4 24
$104.8M
$149.8M
Q3 24
$92.0M
$125.6M
Q2 24
$81.6M
$136.6M
Q1 24
$61.1M
$129.7M
FCF Margin
IAC
IAC
RVTY
RVTY
Q4 25
4.9%
21.0%
Q3 25
4.3%
17.2%
Q2 25
-1.2%
16.0%
Q1 25
-0.8%
16.9%
Q4 24
14.5%
20.5%
Q3 24
14.3%
18.4%
Q2 24
12.9%
19.7%
Q1 24
9.8%
20.0%
Capex Intensity
IAC
IAC
RVTY
RVTY
Q4 25
0.8%
2.6%
Q3 25
0.8%
2.6%
Q2 25
0.8%
2.6%
Q1 25
0.8%
2.4%
Q4 24
0.7%
3.4%
Q3 24
0.5%
3.3%
Q2 24
0.5%
3.2%
Q1 24
0.5%
2.7%
Cash Conversion
IAC
IAC
RVTY
RVTY
Q4 25
1.85×
Q3 25
2.97×
Q2 25
-0.01×
2.49×
Q1 25
3.03×
Q4 24
1.84×
Q3 24
1.57×
Q2 24
2.87×
Q1 24
1.42×
5.67×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

IAC
IAC

Print$168.5M26%
Performance Marketing$101.2M16%
Care.com$85.7M13%
Subscription$69.5M11%
Licensing And Other$43.8M7%
Consumer Revenue$43.2M7%
Advertising$35.9M6%
Project And Other Print$33.6M5%
Advertising Google$28.9M4%
Newsstand$22.4M3%
Emerging Other$19.6M3%

RVTY
RVTY

Immunodiagnostics$240.8M31%
Life Sciences$191.4M25%
Reproductive Health$149.3M19%
Segment Operating Income$132.0M17%
Software$62.3M8%

Related Comparisons